Skip to content
Open access

Real-world effectiveness and safety of lurbinectedin in previously treated small cell lung cancer: results from Jazz EMERGE 402.

Oct 2026 · Lung Cancer · Vol 222, pp. 109644 · 0 citations · 36 references
Medicine

Abstract

Background

In extensive-stage small cell lung cancer (ES-SCLC), lurbinectedin is approved for first-line maintenance treatment with atezolizumab and as monotherapy following disease progression, but prospective real-world data on its use are lacking.

Methods

Jazz EMERGE 402 was a prospective, observational, phase 4 trial (NCT04894591) that evaluated lurbinectedin for previously treated SCLC in a diverse, real-world population. The primary endpoint was overall response rate (ORR). Key secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety.

Results

As of July 17, 2025, 267 patients received ≥ 1 lurbinectedin dose. At baseline, the median age was 67 years, 52 (19%) patients had an Eastern Cooperative Oncology Group score ≥ 2, 67 (25%) had brain metastases, and 88 (33%) had platinum-resistant disease. ORR (95% confidence interval [CI]) was 29% (23%-36%) overall (n = 189) and 33% (25%-42%) in second-line treatment (n = 118). Patients with brain metastases had lower ORR (17% vs 32% without; odds ratio, 0.28 [95% CI: 0.10-0.76]). Median (95% CI) PFS and OS were 3.3 (2.6-4.1) and 7.6 (6.4-8.7) months. OS was shorter with platinum-resistant vs platinum-sensitive disease (5.8 vs 9.3 months; hazard ratio, 1.63 [95% CI: 1.17-2.28]). Eighty-eight (33%) patients had treatment-related adverse events, including anemia (8%) and neutropenia (7%); 21 (8%) discontinued treatment due to adverse events.

Conclusions

In a broad, real-world population with previously treated SCLC, lurbinectedin was associated with clinically meaningful effectiveness and predictable and manageable safety. Lower ORR and OS were seen in patients with brain metastases and platinum-resistant disease, respectively.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.